Beigene, Ltd. ((ONC)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BeiGene, Ltd. is currently conducting a clinical study titled ‘A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy.’ The study aims to assess the effectiveness of zanubrutinib in reducing proteinuria and achieving complete remission in patients with primary membranous nephropathy (PMN) who are receiving optimal supportive care. This research is significant as it explores potential new treatments for PMN, a condition with limited therapeutic options.
The study is testing zanubrutinib, an experimental drug administered orally, either once or twice daily, and comparing it to tacrolimus, an established treatment. Zanubrutinib is intended to provide a new therapeutic option for PMN patients by potentially improving remission rates and reducing proteinuria.
This interventional study is designed with a randomized allocation and a parallel intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment. Participants are divided into different groups to receive either high or low doses of zanubrutinib or tacrolimus.
The study began on April 17, 2023, and is currently recruiting participants. The primary completion date is set for June 23, 2025, which is also the date of the last update. These timelines are crucial for investors as they indicate when significant data might be available, potentially impacting stock performance.
The outcome of this study could influence BeiGene’s stock performance, as positive results might boost investor confidence and market value. Given the competitive landscape in nephrology treatments, successful results could position BeiGene as a leader in this niche, affecting the broader market dynamics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.